High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1-antitrypsin with negligible toxicity

Human Gene Therapy

Volumn 9, Issue 18, 1998, Pages 2709-2716

  Morral, Núria ^a,b   Parks, Robin J ^c   Zhou, Heshan ^a   Langston, Claire ^a   Schiedner, Gudrun ^a,d   Quinones, Janet ^a   Graham, Frank L ^c   Kochanek, Stefan ^a,d   Beaudet, Arthur L ^a,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF COLOGNE   (Germany)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TRANSFER; LIVER; LIVER TOXICITY; MOUSE; NONHUMAN;

ADENOVIRIDAE; ANIMALIA;

EID: 0032506791     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.18-2709     Document Type: Article

References (45)

1. ARMENTANO, D., SOOKDEO, C.C., HEHIR, K.M., GREGORY, R.J., STGEORGE, J.A., PRINCE, G.A., WADSWORTH, S.C., and SMITH, A.E. (1995). Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 6, 1343-1353.
2. BROUGH, D.E., LIZONOVA, A., HSU, C., KULESA, V.A., and KOVESDI, I. (1996). A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70, 6497-6501.
3. BULLARD, D.C., KUNKEL, E.J., KUBO, H., HICKS, M.J., LORENZO, I., DOYLE, N.A., DOERSCHUK, C.M., LEY, K., and BEAUDET, A.L. (1996). Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice. J. Exp. Med. 183, 2329-2336.
4. CHEN, H.H., MACK, L.M., KELLY, R., ONTELL, M., KOCHANEK, S., and CLEMENS, P.R. (1997). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. U.S.A. 94, 1645-1650.
5. CHEN, L., ANTON, M., and GRAHAM, F. (1996). Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat. Cell Mol. Genet. 22, 477-488.
6. CLEMENS, P.R., KOCHANEK, S., SUNADA, Y., CHAN, S., CHEN, H.H., CAMPBELL, K.P., and CASKEY, C.T. (1996). In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3, 965-972.
7. CONNELLY, S., GARDNER, J.M., LYONS, R.M., McCLELLAND, A., and KALEKO, M. (1996). Sustained expression of therapeutic levels of human factor VIII in mice. Blood 87, 4671-4677.
8. 1-Antitrypsin deficiency. In The Metabolic and Molecular Bases of Inherited Disease, 7th Ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, eds. (McGraw-Hill, New York) pp. 2409-2437.
9. DEDIEU, J.-F., VIGNE, E., TORRENT, C., JULLIEN, C., MAHFOUZ, I., CAILLAUD, J.-M., AUBAILLY, N., ORSINI, C., GUILLAUME, J.-M., OPOLON, P., DELAERE, P., PERRICAUDET, M., and YEH, P. (1997). Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71, 4626-4637.
10. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91, 6196-6200.
11. - recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 3, 217-222.
12. FISHER, K.J., CHOI, H., BURDA, J., CHEN, S.-J., and WILSON, J.M. (1996). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22.
13. GAO, G.-P., YANG, Y., and WILSON, J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934-8943.
14. GOLDMAN, M.J., LITZKY, L.A., ENGELHARDT, J.F., and WILSON, J.M. (1995). Transfer of the CFTR gene to the lung of non-human primates with E1-deleted, E2a-defective recombinant adenoviruses: A preclinical toxicology study. Hum. Gene Ther. 6, 839-851.
15. GORZIGLIA, M.I., KADAN, M.J., YEI, S., LIM, J., LEE, G.M., LUTHRA, R., and TRAPNELL, B.C. (1996). Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70, 4173-4178.
16. HAECKER, S.E., STEDMAN, H.H., BALICE-GORDON, R.J., SMITH, D.B.J., GREELISH, J.P., MITCHELL, M.A., WELLS, A., SWEENEY, H.L., and WILSON, J.M. (1996). In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum. Gene Ther. 7, 1907-1914.
17. HARDY, S., KITAMURA, M., HARRIS-STANSIL, T., DAI, Y., and PHIPPS, M.L. (1997). Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71, 1842-1849.
18. HERZ, J., and GERARD, R. (1993). Adenovirus-mediated transfer of low density receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Acad. Natl. Sci. U.S.A. 90, 2812-2816.
19. HIRSCH, S., and GORDON, S. (1983). Polymorphic expression of a neutrophil differentiation antigen revealed by a monoclonal antibody 7/4. Immunogenetics 18, 229-239.
20. ISHIBASHI, S., BROWN, M., GOLDSTEIN, J., GERARD, R., HAMMER, R., and HERZ, J. (1993). Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883-893.
21. JAFFE, H., DANEL, C., LONGENECKER, G., METZGER, M., SETOGUCHI, Y., ROSENFELD, M.A., GANT, T.W., THORGEIRSSON, S.S., STRATFORD-PERRICAUDET, L.D., PERRICAUDET, M., PAVIRANI, A., LECOCQ, J.P., and CRYSTAL, R.G. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nature Genet. 1, 372-378.
22. KAY, M., LI, Q., LIU, T.-J., LELAND, F., TOMAN, C., FINEGOLD, M., and WOO, S.L.C. (1992). Hepatic gene therapy: Persistent expression of human α1-antitrypsin in mice after direct gene delivery in vivo. Hum. Gene Ther. 3, 641-647.
23. 1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 21, 815-819.
24. KNODELL, R.G., ISHAK, K.G., BLACK, W.C., CHEN, T.S., CRAIG, R., KAPLOWITZ, N., KIERNAN, T.W., and WOLLMAN, J. (1981). Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1, 431-435.
25. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.-H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93, 5731-5736.
26. KROUGLIAK, V., and GRAHAM, F.L. (1995). Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum. Gen. Ther. 6, 1575-1586.
27. KUMAR-SINGH, R., and CHAMBERLAIN, J.S. (1996). Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5, 913-921.
28. LIEBER, A., HE, C., KIRILLOVA, I., and KAY, M.A. (1996). Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit biological properties compared with first-gen-eration vectors in vitro and in vivo. J. Virol. 70, 8944-8960.
29. LUSKY, M., RITTNER, K., DIETERLE, A., DREYER, D., MOUROT, B., SCHULTZ, H., STOECKEL, F., PAVIRANI, A., and MEHTALI, M. (1998). In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A or E1/E4 deleted. J. Virol. 72, 2022-2032.
30. MITANI, K., GRAHAM, F.L., CASKEY, C.T., and KOCHANEK, S. (1995). Rescue, propagation and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl. Acad. Sci. U.S.A. 92, 3854-3858.
31. MORRAL, N., O'NEAL, W., ZHOU, H., LANGSTON, C., and BEAUDET, A. (1997). Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther. 8, 1275-1286.
32. MORSY, M.A., ALFORD, E.L., BETT, A., GRAHAM, F.L., and CASKEY, C.T. (1993). Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J. Clin. Invest. 92, 1580-1586.
33. 1 antitrypsin after systemic delivery. Hum. Gene Ther. 9, 1587-1598.
34. PARKS, R.J., CHEN, L., ANTON, M., SANKAR, U., RUDNICKI, M.A., and GRAHAM, F.L. (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570.
35. SCHIEDNER, G., MORRAL, N., PARKS, R., WU, Y., KOOPMANS, S.C., LANGSTON, C., GRAHAM, F.L., BEAUDET, A.L., and KOCHANEK, S. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. 18, 180-183.
36. SMITH, T.A.G., MEHAFFEY, M.G., KAYDA, D.B., SAUNDERS, J.M., YEI, S., TRAPNELL, B.C., McCLELLAND, A., and KALEKO, M. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet. 5, 397-402.
37. STRATFORD-PERRICAUDET, L.D., LEVRERO, M., CHASE, J.F., PERRICAUDET, M., and BRIAND, P. (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum. Gene Ther. 1, 241-256.
38. WANG, Q., JIA, X.-C., and FINER, M.H. (1995). A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 2, 775-783.
39. WANG, Q., GREENBURG, G., BUNCH, D., FARSON, D., and FINER, M.H. (1997). Persistent transgene expression in mouse liver following gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Ther. 4, 393-400.
40. YANG, Y., ERTL, H.C.J., and WILSON, J.M. (1994a). MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1 deleted recombinant adenoviruses. Immunity 1, 433-442.
41. YANG, Y., LI, Q., ERTL, H.C., and WILSON, J.M. (1994b). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
42. YANG, Y., NUNES, F.A., BERENCSI, K., GÖNCZÖL, E., and WILSON, J.M. (1994c). Inactivation of E2a in recombinant adenoviruses limits the cellular immunity and improves the prospect for gene therapy of cystic fibrosis. Nature Genet. 7, 363-369.
43. YANG, Y., LI, Q., ERTL, H.C.J., and WILSON, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
44. YEH, P., DEDIEU, J.F., ORSINI, C., VIGNE, E., DENEFLE, P., and PERRICAUDET, M. (1996). Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70, 559-565.
45. ZHOU, H., O'Neal, W., MORRAL, N., and BEAUDET, A.L. (1996). Development of a complementing cell line and a system for construction of adenoviral vectors deleted for E1 and E2a. J. Virol. 70, 7030-7038.